Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not

professional advice and should not be used in lieu of obtaining advice from a qualified health

care provider. And now on to the show. Welcome to Helix Talk episode 111. I'm your co-host, Dr.

Cain. I'm Dr. Patel. and today with us, we have Dr. Eris

Tolcucci. She is an oncology pharmacist at the Rush University Hospital System.

She's also an assistant professor here at Roslyn Franklin University, and we thought that

she would be the perfect person for today's episode, which is entitled The Basics of Immune

Checkpoint Inhibitors for Non-Oncology Healthcare Providers. That would be you and I, Dr. Patel.

That sounds good because I need a refresher. So Dr. Tokuchi, welcome to the episode.

Thank you, everyone, for having me here today. I'm very excited to talk to you all about the topic at hand.

And I will note that today is actually March 17th. This episode is going to go live on April 7th.

So in a way, we're kind of going in a time machine where right now, you know, the university is locking down.

We're in this remote environment now. And we're kind of making the best of it. So when this

episode goes live on April 7th, hopefully things have calmed down at that point, but there's no way to

know, and we're going to kind of work with what we have today. So why do we get started? And really,

we have a case vignette to kind of kick things off. And this is based on a patient that I saw in the

ICU. And it turns out that this patient was receiving this drug category called immune

checkpoint inhibitors that came out in 2001.

I graduated in 2010.

So I'd never even heard of this chemotherapy agent, let alone some of the side effects

...